Anticarcinogenic actions of tributyrin, a butyric acid prodrug.

Current drug targets (2012-11-13)
Renato Heidor, Juliana Festa Ortega, Aline de Conti, Thomas Prates Ong, Fernando Salvador Moreno

Bioactive food compounds (BFCs) exhibit potential anticarcinogenic effects that deserve to be explored. Butyric acid (BA) is considered a promising BFC and has been used in clinical trials; however, its short half-life considerably restricts its therapeutic application. Tributyrin (TB), a BA prodrug present in milk fat and honey, has more favorable pharmacokinetic properties than BA, and its oral administration is also better tolerated. In vitro and in vivo studies have shown that TB acts on multiple anticancer cellular and molecular targets without affecting non-cancerous cells. Among the TB mechanisms of action, the induction of apoptosis and cell differentiation and the modulation of epigenetic mechanisms are notable. Due to its anticarcinogenic potential, strategies as lipid emulsions, nanoparticles, or structured lipids containing TB are currently being developed to improve its organoleptic characteristics and bioavailability. In addition, TB has minimal toxicity, making it an excellent candidate for combination therapy with other agents for the control of cancer. Despite the lack of data available in the literature, TB is a promising molecule for anticancer strategies. Therefore, additional preclinical and clinical studies should be performed using TB to elucidate its molecular targets and anticarcinogenic potential.

Product Number
Product Description

Butyric acid, ≥99%
Butyric acid, natural, ≥99%, FCC, FG
Butyric acid, analytical standard
Glyceryl tributyrate, ≥99%
Tributyrin, 97%, FG
Glyceryl tributyrate, puriss., ≥98.5% (GC)
Butyric acid, ≥99%, FG